drugset / Trial / NCT06530082
A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to understand the safety and tolerability of CircFAM53B-219aa DC vaccine monotherapy and its combination with camrelizumab in the treatment of HER2-negative advanced breast cancer, as well as to evaluate its efficacy.
Timeline
- Start
- 2024-12-01
- Primary completion
- 2026-04-01
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | CircFam53B-219aa DC vaccine | Vaccine | 5e+06 cells | Other |
| Subject | CircFam53B-219aa DC vaccine | Vaccine | 1.5e+07 cells | Other |
| Subject | CircFam53B-219aa DC vaccine | Vaccine | 4e+07 cells | Other |